Parsley Energy (PE) Shareholder Proxima Capital Management Boosted Its Position by $1.95 Million as Shares Declined; Fernwood Investment Management Lowered Holding in Portola Pharmaceuticals Com (PTLA) by $502,200

February 23, 2018 - By Moses P. Lee

Youlia Miteva increased its stake in Parsley Energy Inc (PE) by 34.88% based on its latest 2017Q3 regulatory filing with the SEC. Proxima Capital Management Llc bought 75,000 shares as the company’s stock declined 0.66% while stock markets rallied. The hedge fund run by Youlia Miteva held 290,000 shares of the energy company at the end of 2017Q3, valued at $7.64M, up from 215,000 at the end of the previous reported quarter. Proxima Capital Management Llc who had been investing in Parsley Energy Inc for a number of months, seems to be bullish on the $7.87 billion market cap company. The stock increased 8.40% or $1.94 during the last trading session, reaching $25.04. About 10.94M shares traded or 100.48% up from the average. Parsley Energy, Inc. (NYSE:PE) has risen 26.09% since February 23, 2017 and is uptrending. It has outperformed by 9.39% the S&P500.

Fernwood Investment Management Llc decreased its stake in Portola Pharmaceuticals Inc Com (PTLA) by 3.89% based on its latest 2017Q3 regulatory filing with the SEC. Fernwood Investment Management Llc sold 9,300 shares as the company’s stock rose 22.73% with the market. The institutional investor held 229,577 shares of the health care company at the end of 2017Q3, valued at $12.40 million, down from 238,877 at the end of the previous reported quarter. Fernwood Investment Management Llc who had been investing in Portola Pharmaceuticals Inc Com for a number of months, seems to be less bullish one the $2.94B market cap company. The stock increased 0.24% or $0.11 during the last trading session, reaching $45.02. About 775,191 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since February 23, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Investors sentiment decreased to 1.13 in Q3 2017. Its down 0.27, from 1.4 in 2017Q2. It dived, as 51 investors sold PE shares while 91 reduced holdings. 49 funds opened positions while 111 raised stakes. 246.67 million shares or 3.47% more from 238.40 million shares in 2017Q2 were reported. Loomis Sayles And Co LP accumulated 982,065 shares or 0.06% of the stock. Susquehanna Interest Grp Ltd Liability Partnership owns 95,337 shares for 0% of their portfolio. 1.61 million were reported by Westwood Holdings Gp. Teacher Retirement System Of Texas, Texas-based fund reported 7,928 shares. Mufg Americas Holding holds 400 shares. 25,019 were accumulated by Magnetar Financial Ltd. Credit Suisse Ag invested in 702,430 shares. Ardsley Advisory Prns owns 600,000 shares for 2.1% of their portfolio. Tiaa Cref Inv Mngmt Lc invested 0.16% of its portfolio in Parsley Energy, Inc. (NYSE:PE). Td Asset Mngmt owns 21,350 shares for 0% of their portfolio. Clearbridge Invests Limited Liability Corporation has 0.07% invested in Parsley Energy, Inc. (NYSE:PE) for 2.69 million shares. Fmr Ltd reported 11.99 million shares. 1492 Capital Mngmt Ltd Llc holds 0.37% or 15,839 shares in its portfolio. Quantbot Limited Partnership owns 16,641 shares or 0.04% of their US portfolio. Schwab Charles Inv Management invested in 721,002 shares.

Among 36 analysts covering Parsley Energy Inc (NYSE:PE), 29 have Buy rating, 0 Sell and 7 Hold. Therefore 81% are positive. Parsley Energy Inc had 127 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Friday, November 6 by Northland Capital. Macquarie Research downgraded Parsley Energy, Inc. (NYSE:PE) on Wednesday, October 12 to “Neutral” rating. The rating was reinitiated by UBS with “Buy” on Thursday, March 23. The firm earned “Outperform” rating on Tuesday, September 13 by FBR Capital. Credit Suisse maintained it with “Outperform” rating and $25 target in Wednesday, March 2 report. The stock of Parsley Energy, Inc. (NYSE:PE) has “Overweight” rating given on Tuesday, June 21 by Barclays Capital. The rating was maintained by RBC Capital Markets with “Buy” on Friday, November 10. Deutsche Bank maintained the stock with “Buy” rating in Tuesday, June 14 report. The firm has “Outperform” rating given on Thursday, November 9 by Imperial Capital. On Tuesday, August 15 the stock rating was maintained by Citigroup with “Buy”.

Proxima Capital Management Llc, which manages about $1.13B and $178.98 million US Long portfolio, decreased its stake in Kraton Corporation (NYSE:KRA) by 17,100 shares to 273,600 shares, valued at $11.06M in 2017Q3, according to the filing. It also reduced its holding in Marathon Oil Corp (NYSE:MRO) by 145,000 shares in the quarter, leaving it with 200,000 shares, and cut its stake in Herc Hldgs Inc.

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 35 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse on Tuesday, December 27 with “Outperform”. Goldman Sachs downgraded the stock to “Neutral” rating in Monday, March 28 report. The firm earned “Buy” rating on Wednesday, September 20 by Credit Suisse. The rating was maintained by Oppenheimer on Tuesday, December 19 with “Buy”. Credit Suisse upgraded the stock to “Outperform” rating in Thursday, August 24 report. The company was maintained on Thursday, August 10 by Credit Suisse. On Tuesday, May 31 the stock rating was downgraded by Credit Suisse to “Neutral”. The firm earned “Buy” rating on Thursday, December 28 by Oppenheimer. The firm earned “Buy” rating on Monday, June 26 by Morgan Stanley. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Oppenheimer on Monday, June 26.

Investors sentiment increased to 2.16 in Q3 2017. Its up 0.85, from 1.31 in 2017Q2. It improved, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Hanseatic Management Services Inc stated it has 0.33% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Cubist Systematic Strategies Llc stated it has 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Rhumbline Advisers stated it has 64,689 shares or 0.01% of all its holdings. Renaissance Limited Co owns 528,500 shares. Hoertkorn Richard Charles holds 0.02% or 500 shares. Credit Agricole S A reported 37,500 shares stake. Valley Natl Advisers Incorporated has invested 0.02% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). State Bank Of New York Mellon holds 334,027 shares. First Personal Fincl holds 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 1,016 shares. Citadel Advsr Limited Liability Corp invested in 0.04% or 1.05 million shares. State Street stated it has 2.40 million shares or 0.01% of all its holdings. Evanson Asset Lc holds 0.06% or 5,000 shares in its portfolio. Meeder Asset Inc reported 0% stake. Alliancebernstein Ltd Partnership has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Aperio Lc accumulated 4,414 shares.

Since December 15, 2017, it had 0 buys, and 1 insider sale for $563,950 activity.

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on February, 28 after the close. They expect $-1.52 earnings per share, down 60.00% or $0.57 from last year’s $-0.95 per share. After $-1.41 actual earnings per share reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.80% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Moses P. Lee

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: